Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
In the STEP-1 trial (adults with obesity/overweight without diabetes), average weight loss at 68 weeks was ~14.9% with semaglutide 2.4 mg vs ~2.4% with placebo
The FDAs decision opens the door to Medicare coverage of Wegovy, which was first approved by the FDA as an anti-obesity medication
The grey market for tirzepatide has exploded
doi:10.1038/s41366-020-00728-8
Retatrutide is an investigational once-weekly injectable triple receptor agonist activating GLP-1, GIP, and glucagon receptors to reduce appetite, improve insulin secretion, and increase energy expenditure
While the relative risk reduction tended to be largest with low CV risk score, the largest absolute risk reduction was for intermediate to high CV risk score
US$ 23.29
US$ 20.54
US$ 20.33
